Lindsay Fischer is an Associate Editor for CURE Media Group, Oncology Nursing News, and OncLive. With a focus on oncology, Lindsay's articles cover a wide range of topics including treatment options, research breakthroughs, patient care, and nursing practices. Her work has also been featured in Targeted Oncology and Cancer Network.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Lindsay Fischer's consistent coverage of healthcare and pharmaceutical topics, with a focus on data-driven insights and expert commentary, indicates that she is likely to be responsive to pitches offering in-depth analysis or interviews from reputable experts in the field. With a strong emphasis on citing data, providing evidence-based research or access to credible sources will enhance the chances of effective outreach.
As Lindsay does not have a specified geographic focus, pitches should address international developments within healthcare and pharmaceuticals. Additionally, given her frequent use of press releases as content sources, organizations promoting new studies or drug approvals may find success by sharing their latest findings for potential coverage.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Kristin Daly, MSN, ANP-BC, AOCNP, explains how providers approach staging and treatment decision-making in head and neck cancer.
By: Lindsay Fischer
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
By: Lindsay Fischer
The FDA has approved belzutifan to treat patients with advanced renal cell carcinoma (RCC) who have already undergone PD-1 or PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor.
By: Lindsay, Fischer
For patients with gynecologic cancer for whom platinum-based chemotherapy is no longer effective, antibody-drug conjugates are an exciting second-line option.
By: Lindsay Fischer
During a Case-Based Roundtable™ event, Beth Faiman, Phd, CNP, and participants discussed the use of combination therapies, including daratumumab, as frontline therapy for patients with transplant-ineligible multiple myeloma.
By: Lindsay Fischer
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, discusses the growing number of new therapies for patients with relapsed or refractory multiple myeloma.
By: Lindsay Fischer
Kizzie Charles, MS, APRN, AGCNS-BC, CNOR, walks through the process of developing a successful quality improvement project in the perioperative oncology setting.
By: Lindsay Fischer
Amy Martinez, BSN, RN, OCN, explains how her team incorporated the Timed-Up-and-Go test into their workflows on a radiology unit.
The pain and suffering that Eduardo Bruera, MD, FAAHPM, witnessed in patients during his clinical oncology rotations motivated him to reshape palliative care treatment.
By: Lindsay Fischer
Bispecific antibodies that engage T cells are an effective treatment modality in relapsed/refractory disease and are an important new treatment for relapsed large B-cell lymphoma.
(833) 317-6278 
